Compare EIC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | BWAY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.4M | 450.8M |
| IPO Year | N/A | N/A |
| Metric | EIC | BWAY |
|---|---|---|
| Price | $9.98 | $24.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.00 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 166.9K | 79.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.27 | $314.08 |
| Revenue Next Year | N/A | $23.37 |
| P/E Ratio | ★ $9.08 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.78 | $7.84 |
| 52 Week High | $16.05 | $26.63 |
| Indicator | EIC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 52.86 |
| Support Level | $9.78 | $14.79 |
| Resistance Level | $11.34 | $25.71 |
| Average True Range (ATR) | 0.24 | 1.39 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 31.08 | 35.03 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.